1Adams J,Palombella VJ,Sausville EA,et al.Proteasome inhibitors: a novel class of potent and effective antitumor agents.Cancer Res,1999,59(11):2615-2622.
2Baldwin AS.Control of oncogenesis and cancer therapy resistance by the transcription factor NF-kappaB.J Clin Invest,2001,107(3):241-246.
3Fennell DA.Bcl-2 as a target for overcoming chemoresistance in small-cell lung cancer.Clin Lung Cancer,2003,4(5):307-313.
4Huang CI,Neuberg D,Johnson BE.Expression of bcl-2 protein is associated with shorter survival in nonsmall cell lung carcinoma.Cancer,2003,98(1):135-143.
5Bold RJ,Virudachalam S,McConkey DJ.Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome.J Surg Res,2001,100(1):11-17.
6Denlinger CE,Keller MD,Mayo MW et al.Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer,J Thorac Cardiovasc Surg,2004,127(4):1078-1086.
7Yang Y,Ikezoe T,Saito T,et al.Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling.Cancer Sci,2004,95(2):176-180.
8Teicher BA,Ara G,Herbst R,et al.The proteasome inhibitor PS-341 in cancer therapy.Clin Cancer Res,1999,5(9):2638-2645.
9Wang CY,Cusack JC Jr,Liu R,et al.Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaB.Nat Med,1999,5(4):412-417.
10Shah SA,Potter MW,McDade TP,et al.26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer.J Cell Biochem,2001,82(1):110-122.
